RESUMEN
To study the effect of intravitreal avastin on systemic blood pressure in controlled hypertensive patients. This is a retrospective study to evaluate blood pressure changes in hypertensive patients with ischemic ocular pathologies after a 0.05 ml [1.25 mg] intravitreal avastin injection. It included 40 patients with retinal vascular diseases; their blood pressure was measured before the treatment [IVA] as a baseline, and then it was measured after 1 day, 1 week, 4 weeks, and then monthly for at least 3 months. All patients were given the same concentration of avastin intravitreally [0.05 ml], and their blood pressure was measured in supine position using the digital sphygmomanometer. The elevation in blood pressure was noted in 90% of the patients from the baseline on the first day postinjection. No significant changes were observed on blood pressure in 1 week, 4 weeks, and other readings postinjection. Treating ocular vascular diseases with intravitreal avastin is safe in controlled hypertensive patients